Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript) | seekingalpha.com • |
Biocept to Hold Business Update Conference Call on August 30, 2023 | businesswire.com • |
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole | investorplace.com • |
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference | proactiveinvestors.com • |
Biocept appoints Antonino Morales as president and chief executive officer | proactiveinvestors.com • |
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023 | businesswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-20 | 2023-09 | 0 | N/A | N/A | N/A |
2023-05-10 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-21 | 2022-09 | -4.8 | N/A | N/A | N/A |
2022-11-10 | 2022-06 | 0 | N/A | N/A | N/A |
2022-05-23 | 2022-03 | -7.21 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-12-08 | HALE DAVID F | Director | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Anson Funds Management LP | 44.86K | 54.28K | 1.71% |
2023-06-29 | Boothbay Fund Management, LLC | 23.53K | 28.47K | 0.90% |
2023-06-29 | Tower Research Capital LLC (TRC) | 5.39K | 6.52K | 0.21% |
2023-06-29 | Blackrock Inc. | 5.26K | 6.37K | 0.20% |
2023-06-29 | Acadian Asset Management. LLC | 247.00 | 298.00 | 0.01% |
2023-06-29 | Group One Trading, L.P. | 270.00 | 326.00 | 0.01% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 4.43K | 5.37K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.95K | 6.38K | 0.11% |
2023-05-30 | Fidelity Series Total Market Index Fund | 644.00 | 1.39K | 0.02% |
2023-05-30 | Fidelity Total Market Index Fund | 488.00 | 1.05K | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 189.00 | 408.00 | 0.01% |
Split | Date |
---|---|
1 : 30 | 2023-05-17 |
1 : 10 | 2020-09-08 |
1 : 30 | 2018-07-10 |
1 : 3 | 2016-09-29 |
-
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for $1.0 billion upfront -- PTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 million -- Transaction expected to enhance long-term Adjusted Cash Receipts growth (non-GAAP) -- Royalty Pharma to host conference call today, Thursday, October 19 at 9:00am EDT NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
-
The stock has been doing this for years. They do an offering every time it goes down to nothing. I wouldn’t put a dollar in it.
-
$IBIOL
-
Liking this more and more! Loading all I can
-
Double bottom, let’s go now!
-
This company ruins stock price every two years does a r/s then repeats look at history they been scamming for years promising a dream
-
Everyone who has been mislead and scammed by this company should file a complaint with the SEC; and also call Biocept investor relations at the following: CONTACT BIOCEPT, INC.
Biocept, Inc. Headquarters
9955 Mesa Rim Road
San Diego, CA 92121
Phone: 858.320.8200
Fax: 858.320.8225
Email: IR@biocept.comLHA Investor Relations
Jody Cain
310.691.7107
jcain@lhai.com -
How has this fraudulent company gotten away with all these reverse stock splits for all these years; why have they not been reported and investigated by SEC!? I have invested in this horrible company for 3yrs and they have already done two reverse stock splits within tjat short time, the first was a 1 for 10 reverse splitand now they just did a 1 for 30, I went from having 30k shares to 166, my $34k investment has gotten wiped out just like that, this will have to go up to $205/share for me to recoup my hard earned money, shame on them and hope they go to prison for committing fraud and misleading investors that trusted and believed in them!!!
-
This stock is a joke I have lost so much
-
I already lost a boat load on there last r/s good luck. Hate say it this stock does r/s almost every 2 years then does 10 to 1 then in 2 more years back down under 1$ I love there technology but the ceo needs to go he been trying for years after years look at chart it always goes straight down
-
Don’t fall for these assholes trying to talk u in to this shit hole stock even if you are retarded just. Go back two years same people that short it. Keep trying tell u to buy it this is a Mooney pit it’s a great short stay away if u don’t wanna lose I lose 20,000 in the last reverse split same clowns saying oh covid testing gonna make it fly lol what a lie they need a new ceo and. Yes this is going under a 1$. Like it always does then nail does reverse split like he’s been doing there plan sounds great but formula don’t profit
-
I don’t get how people still invest in this I lost so much money last year here and the year before look at the charts this company been bleeding to nothing then dilution r/s to get it back up all on investors coin look for yourself. Then they said covid testing would save the day still it bleeds just trying warn you all I already took my L
-
Corrupt elite Jews own everything , control everything.
-
Corrupt Jews that control this market must go
-
To many retards bought options
-
It’s not this stock , it’s not this sector , it’s not pump and dumpers, it’s not bears or bulls .
It’s simply the corrupt elites that control our world . They do what they want when they want with 0 repercussions. They just play the opposite side that retails on and over power us.
Government = corrupt
-
Hint: Need Vaccine every year for whole world like flu shot.! Why? See bellow:
1: To save the people
2: To save Jobs
3: To save the business
4: To Save the Companies
5: To Save the cities
6: To save the Countries
7: To save the Continent
8: To save the World
9: To save the Economy
10: Save the planet
Note: if you would need painkiller with would you take same frequency as you are taking ??????
I would love $VXRT
Important note: Sorry who sold this morning and pre market. -
In my opinion All cryptos will hit 50% + EOY. (Invest with your own risk/reward and DD).Get 10% bonus at following link in Binance . Their savings rate for USDT , BNB in more that 6.30%, bank rate is 0.05% !!!!!! Hahaha
https://accounts.binance.com/en/register?ref=NPF0TKH6 -
Need more volume buy #BIOC next runner upto $7
-
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
seekingalpha.com • -
Biocept to Hold Business Update Conference Call on August 30, 2023
businesswire.com • -
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
investorplace.com • -
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
proactiveinvestors.com • -
Biocept appoints Antonino Morales as president and chief executive officer
proactiveinvestors.com • -
Why Is Biocept (BIOC) Stock Down 42% Today?
investorplace.com • -
Biocept shares to commence trading on split-adjusted basis
proactiveinvestors.com • -
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Biocept reports 176% year-over-year jump in orders for CNSide assay
proactiveinvestors.com • -
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
proactiveinvestors.com • -
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
proactiveinvestors.com • -
Biocept to Hold Business Strategy Conference Call Today
businesswire.com • -
Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services
proactiveinvestors.com • -
Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
proactiveinvestors.com • -
Biocept reports unaudited net revenue of $61.2 million for 2021
proactiveinvestors.com • -
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
proactiveinvestors.com • -
Biocept appoints Darrell Taylor as its new chief compliance officer
proactiveinvestors.com • -
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
proactiveinvestors.com • -
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
proactiveinvestors.com • -
Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing
proactiveinvestors.com • -
7 of the Best Penny Stocks to Buy Coming Into Year-End
investorplace.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept reports profitability for the first half on back of increased COVID-19 testing
proactiveinvestors.com • -
Biocept appoints David Karlander as senior vice president of Commercial Operations
proactiveinvestors.com • -
Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman
proactiveinvestors.com • -
Biocept joins the Russell Microcap Index
proactiveinvestors.com • -
Biocept Joins the Russell Microcap® Index
businesswire.com • -
Wall Street takes a turn for the worse as investors eye Fed
proactiveinvestors.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept makes coronavirus testing available for California's 116 community colleges
proactiveinvestors.com • -
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
proactiveinvestors.com • -
Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing
proactiveinvestors.com • -
Biocept: Record Revenues And Profits Support Speculative Buy
seekingalpha.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept: Q4 Earnings Insights
benzinga.com • -
Biocept to Participate in Three Virtual Investment Conferences in March
businesswire.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
prnewswire.com • -
Analyzing Teleflex (NYSE:TFX) & Viatar CTC Solutions (NYSE:VRTT)
thelincolnianonline.com •